Senzar Asset Management adds Biogen Inc (BIIB) to its portfolio

Biogen Inc (BIIB) : Senzar Asset Management added new position in Biogen Inc during the most recent quarter end. The investment management firm now holds 101,600 shares of Biogen Inc which is valued at $31,896,304 , the company said in a statement filed on Aug 12, 2016 with the SEC.Biogen Inc makes up approximately 6.34% of Senzar Asset Management’s portfolio.

Other Hedge Funds, Including , Dubuque Bank Trust Co reduced its stake in BIIB by selling 90 shares or 17.01% in the most recent quarter. The Hedge Fund company now holds 439 shares of BIIB which is valued at $137,820. Biogen Inc makes up approx 0.03% of Dubuque Bank Trust Co’s portfolio.Ajo Lp boosted its stake in BIIB in the latest quarter, The investment management firm added 99,758 additional shares and now holds a total of 140,331 shares of Biogen Inc which is valued at $44,014,818. Biogen Inc makes up approx 0.19% of Ajo Lp’s portfolio.Ashfield Capital Partners reduced its stake in BIIB by selling 4,439 shares or 10.16% in the most recent quarter. The Hedge Fund company now holds 39,262 shares of BIIB which is valued at $12,347,506. Biogen Inc makes up approx 0.94% of Ashfield Capital Partners’s portfolio.

Biogen Inc closed down -2.04 points or -0.66% at $306.13 with 10,44,953 shares getting traded on Monday. Post opening the session at $307.87, the shares hit an intraday low of $304.79 and an intraday high of $309.135 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.

Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.

Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Biogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Biogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.